Kane Biotech (CVE:KNE) Trading Down 14.3% – Time to Sell?

Kane Biotech Inc. (CVE:KNE)’s stock price traded down 14.3% during trading on Friday . The stock traded as low as C$0.03 and last traded at C$0.03. 119,545 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 173,620 shares. The stock had previously closed at C$0.04.

Kane Biotech Trading Down 14.3%

The business’s 50-day moving average price is C$0.03 and its two-hundred day moving average price is C$0.04. The company has a market capitalization of C$5.02 million, a P/E ratio of -0.38 and a beta of 1.04. The company has a debt-to-equity ratio of -289.57, a current ratio of 0.90 and a quick ratio of 0.39.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.